Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience

por Gaviani, P., Simonetti, G., Salmaggi, A., Lamperti, E., Silvani, A.
Publicado 2013

Clinical management of grade III oligodendroglioma

por Simonetti, G, Gaviani, P, Botturi, A, Innocenti, A, Lamperti, E, Silvani, A
Publicado 2015

KS02.5.A COVID19 impact on the neuro-oncological population. evaluation of critical issues and resources of patients and caregivers

por Anghileri, E, Tramacere, I, Morlino, S, Leuzzi, C, Pareja Gutierrez, L, Fariselli, L, Silvani, A, Berrini, F
Publicado 2022

Neoplastic Meningitis from Solid Tumors: A Prospective Clinical Study in Lombardia and a Literature Review on Therapeutic Approaches

por Silvani, A., Caroli, M., Gaviani, P., Fetoni, V., Merli, R., Riva, M., De Rossi, M., Imbesi, F., Salmaggi, A.
Publicado 2013

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.

por Negri, D. R., Tosi, E., Valota, O., Ferrini, S., Cambiaggi, A., Sforzini, S., Silvani, A., Ruffini, P. A., Colnaghi, M. I., Canevari, S.
Publicado 1995